Interestingly, Ky1043 has been shown to preferentially expand TCF1+ PD-1+ precursor exhausted CD8+ T cells (Tpex) in mouse tumor models (166) that have been correlated with successful responses to immunotherapies. Here, CD8A is linked to neoplasm.